Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M89.6Revenue (TTM) $M12.9Net Margin (%)-104.1Altman Z-Score-0.0
Enterprise Value $M98.4EPS (TTM) $-0.2Operating Margin %-144.5Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.1Pre-tax Margin (%)-127.1Higher ROA y-yY
Price/Book2.310-y EBITDA Growth Rate %--Quick Ratio2.4Cash flow > EarningsY
Price/Sales6.85-y EBITDA Growth Rate %177Current Ratio3.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-18.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-31.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M77.9ROIC % (ttm)-54.1Gross Margin Increase y-yN

Gurus Latest Trades with NEPT

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

NEPT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


NEPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Montgomery, Adrian TaylorDirector 2014-12-03Buy11,000$2.21-47.96view
Godin, AndrSenior Officer 2014-11-12Buy3,000$2.15-46.51view
Lemieux, PierreDirector or Senior Officer of Insider or Subsidiar 2014-11-12Buy5,000$2.19-47.49view
Godin, AndrSenior Officer 2014-11-11Buy8,000$2.12-45.75view
Ripplinger, JohnSenior Officer 2014-11-11Buy3,550$2.12-45.75view
Turcotte, MarioSenior Officer 2014-11-11Buy6,870$2.14-46.26view
Fitzgibbon, PierreDirector 2014-11-10Buy37,500$2.09-44.98view
Huart, BenoîtDirector 2014-11-10Buy7,000$2.03-43.35view
Lauzon, ClaudieSenior Officer 2014-11-10Buy2,400$2.08-44.71view
Le Bel, DominiqueSenior Officer 2014-11-10Buy10,000$2.01-42.79view

Press Releases about NEPT :

Quarterly/Annual Reports about NEPT:

    News about NEPT:

    Articles On GuruFocus.com
    What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

    More From Other Websites
    Acasti Announces Fourth Quarter and Fiscal Year Results May 25 2016
    Neptune Announces Fourth Quarter and Fiscal Year Results May 25 2016
    Neptune to Hold Conference Call to Discuss Fourth Quarter and Year-End Results May 13 2016
    Jan D'Alvise Appointed President & CEO of Acasti Pharma May 12 2016
    Neptune Announces Term Loan Financing Apr 20 2016
    Neptune Announces Term Loan Financing Apr 20 2016
    Neptune Announces Preliminary Q4 Results Record Revenue and Positive Adjusted EBITDA Apr 05 2016
    Neptune Pops And Drops After New Guidance Apr 05 2016
    Neptune Announces Preliminary Q4 Results Apr 05 2016
    Nasdaq Grants Acasti Cure Period to Regain Compliance with Audit Committee Membership Requirements Mar 25 2016
    Acasti Announces Management Appointment and Changes to the Board of Directors Mar 01 2016
    Acasti Announces Share-for-Debt Feb 05 2016
    Neptune Tech reports 3Q loss Jan 12 2016
    Neptune Tech reports 3Q loss Jan 12 2016
    Neptune Acquires Biodroga, Creating New Growth Platform Jan 07 2016
    NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. Financials Dec 08 2015
    Neptune Announces Preliminary Q3 Results Dec 07 2015
    ow.ly/Uq9vG Nov 10 2015
    Neptune Technologies & Bioresources, Inc. Earnings Q2, 2016 Oct 19 2015
    Neptune Announces Second Quarter Results Oct 15 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)